

NOVYRA PHARMACHEM LIMITED

(Formerly known as Bansisons Tea Industries Limited)

Regd. Office: R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound B/h
Zenith Mill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India, 395004
CIN: L21001GJ1987PLC171085, Email: bansisonstea@gmail.com, Website:
www.bansisonstea.com, Contact : 9265453481

January 26, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: - 519353

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on January 26, 2026

Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their meeting held on today i.e. Monday, January 26, 2026 at the Registered Office of the Company *inter-alia* has, considered and approved the following: -

1. Un-Audited Financial Results of the Company for the Third Quarter and Nine months ended December 31, 2025, along with Auditors' Limited Reports, in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.
2. Reviewed the business of the company.

The Board Meeting commenced at 05:30 P.M. and concluded at 07:00 p.m.

You are requested to take the above information on records and disseminate the same on your respective websites.

Thanking you,
Yours faithfully,

For Bansisons Tea Industries Limited

Hiren Dhirajlal Shah
Director
DIN: 09842161



Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended)

**To Board of Directors of
Novyra Pharmachem Limited (Formely as Bansisons Tea Industries Limited)**

We have reviewed the accompanying statement of unaudited financial results of **Novyra Pharmachem Limited (Formely as Bansisons Tea Industries Ltd)** (the "Company") for the quarter ended December 31, 2025 and year to date from April 01, 2025, to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors at their meeting held on **26th January 2026**, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" (Ind AS 34), as prescribed under section 133 of the Companies Act, 2013 as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review of the Statement conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.
Chartered Accountants
Firm Regn. No. 0112187W



Hiren Maru
Partner
Membership No. 115279
UDIN: 26115279XWJMLH7561
Date: 26-01-2026
Place: Mumbai

Office Address: Office No. 10, Vihang Vihar, Opp. Gautam Park, Panchpakhadi, Thane (West) – 400 602, Maharashtra, India.

Cell: +91 9320268900 Ph.: 022 4601 2965 / 2545 2965 Email: hirenmarn@yahoo.co.uk

NOVYRA PHARMACHEM LIMITED

(Formerly known as Bansions Tea Industries Limited)
 Regd. Office: P.S. No 432, City Suresh, No 3763 Ground Floor Pavithrawala Compound B/h
 Zenith Mill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India, 395004
 CIN:L21001GJ1987PLC171085, Email: bansionsstea@gmail.com, Website:
 www.bansionsstea.com, Contact : 9265453481

Statement of unaudited Standalone Financial Results for the Quarter ended December 31, 2025

Particulars	(Rs. In Lakhs)					
	Quarter Ended			Nine Month Ended		For The Year Ended
	12/31/2025	9/30/2025	12/31/2024	12/31/2025	12/31/2024	3/31/2025
A Date of start of reporting period	10/1/2025	7/1/2025	10/1/2024	4/1/2025	4/1/2024	4/1/2024
B Date of end of reporting period	12/31/2025	9/30/2025	12/31/2024	12/31/2025	12/31/2024	31/3/2025
C Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue From Operations						
(a) Revenue From Operations	-	-	-	-	-	-
(b) Other Income	-	2.22	-	6.31	-	4.80
Total Revenue from operations (net)	-	2.22	-	6.31	-	4.80
Expenditure						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchases of stock-in-trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d) Employee benefit expense	0.39	0.36	0.53	3.25	0.53	3.84
(e) Finance Costs	-	-	-	-	-	-
(e) Depreciation and amortisation expense	0.73	0.73	-	2.18	-	3.34
(f) Other Expenses	0.03	-	0.35	2.70	0.81	3.97
Total expenses	1.15	1.09	0.88	8.13	1.34	11.16
Profit (loss) Before exceptional & Extraordinary items and Tax	(1.15)	1.13	(0.88)	(1.82)	(1.34)	(6.36)
Exceptional items	-	-	-	-	-	-
Profit (loss) from ordinary activities before tax	(1.15)	1.13	(0.88)	(1.82)	(1.34)	(6.36)
Tax Expenses - Current Tax	-	-	-	-	-	-
(less):- MAT Credit	-	-	-	-	-	-
Current Tax Expense Relating to Prior Years	-	-	-	-	-	-
Deferred Tax (Assets)/liabilities	-	-	-	-	-	-
Profit (loss) from ordinary activities	(1.15)	1.13	(0.88)	(1.82)	(1.34)	(6.36)
Other Comprehensive Income (OCI)						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss	-	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Profit After Other Comprehensive Income	(1.15)	1.13	(0.88)	(1.82)	(1.34)	(6.36)
Profit/(Loss) From Discontinuing Operation Before Tax	-	-	-	-	-	-
Tax Expenses of Discontinuing Operations	-	-	-	-	-	-
Net Profit/(Loss) from Discontinuing Operation After Tax	-	-	-	-	-	-
Profit/(Loss) For Period Before Minority Interest	-	-	-	-	-	-
Share Of Profit / Loss Associates	-	-	-	-	-	-
Profit/Loss Of Minority Interest	-	-	-	-	-	-
Net Profit (+)/ Loss (-) For the Period	(1.15)	1.13	(0.88)	(1.82)	(1.34)	(6.36)
Details of equity share capital						
Paid-up equity share capital	630.00	630.00	619.75	630.00	619.75	619.75
Face value of equity share capital (per share)	10.00	10.00	10.00	10.00	10.00	10.00
Reserve Excluding Revaluation Reserves As Per Balance sheet Of previous Year	-	-	-	-	-	-
Earnings per share (EPS)						
Basic earnings per share from continuing And Discontinuing operations	(0.02)	0.02	(0.01)	(0.03)	(0.02)	(0.10)
Diluted earnings per share from continuing And Discontinuing operations	(0.02)	0.02	(0.01)	(0.03)	(0.02)	(0.10)

Notes:-

- The above said financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective Meetings held on 26th January, 2026.
- The Statutory Auditors have carried out limited review of the Unaudited Results of the Company for the Quarter ended 31/12/2025.
- These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.
- The Company has no reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.
- Statement of Assets and Liabilities and cashflow statement as on 30th September 2025 is enclosed herewith.
- The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

For Bansions Tea Industries Limited

Hiren Dhirajlal Shah
 Hiren Dhirajlal Shah
 Director
 DIN: 09642161



Date :- 26-01-2026

Place :- Surat